Roy Baynes, Merck
FDA bats back Merck’s ‘pipeline in a product,’ demands more efficacy data
Despite some heavy blowback from analysts, Merck execs maintained an upbeat attitude about the market potential of its chronic cough drug gefapixant. But the confidence …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
